. [82] to assess the efficacy, security and tolerability of Cannabidiol as an adjunct therapy in conjunction with anti-epileptic medicines within the patients suffering from tuberous sclerosis complicated whose most frequent neurological symptom is epilepsy. Within this scientific trial research